Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price objective lifted by Deutsche Bank Aktiengesellschaft from $25.00 to $28.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 26.59% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Leerink Partners decreased their price target on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating for the company in a research note on Tuesday, February 24th. Needham & Company LLC raised shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Monday. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Finally, Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $29.70.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $22.12 on Tuesday. The firm has a market cap of $5.04 billion, a PE ratio of 43.37, a price-to-earnings-growth ratio of 3.01 and a beta of 2.56. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $70.43. The firm’s 50-day simple moving average is $24.51 and its 200-day simple moving average is $37.89. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. The business had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.11 EPS. Equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has initiated a share repurchase program on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Activity

In related news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the completion of the transaction, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 80,463 shares of company stock worth $2,846,696. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Farallon Capital Management LLC grew its holdings in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. Invesco Ltd. boosted its stake in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after acquiring an additional 2,128,587 shares during the last quarter. Norges Bank acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $62,153,000. Clear Street LLC acquired a new position in Hims & Hers Health in the second quarter valued at about $83,582,000. Finally, Clear Street Group Inc. bought a new position in Hims & Hers Health during the 3rd quarter worth approximately $87,372,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Deal ends legal dispute and opens product distribution — Novo Nordisk agreed to drop current proceedings and will distribute Wegovy and Ozempic on Hims’ platform, removing a major regulatory/legal overhang and creating a direct revenue and margin runway for Hims. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Market confirmation and coverage — Major outlets (CNBC, Yahoo, Bloomberg) reported the truce and distribution plan, accelerating institutional and retail buying as the revenue path became clearer. Hims & Hers shares surge after Novo Nordisk ends legal feud
• Positive Sentiment: Analyst upgrade — Needham upgraded HIMS from Hold to Buy with a $30 target, signaling buy‑side support and providing a fresh price catalyst. Benzinga coverage of Needham upgrade
• Neutral Sentiment: Short interest and squeeze dynamics — Commentators note very high short interest and the potential for an additional short squeeze; that can amplify gains but also increases volatility and downside risk when the squeeze unwinds. Seeking Alpha: Short squeeze discussion
• Neutral Sentiment: Strategic concession details — Reporting indicates Hims agreed to stop advertising compounded GLP‑1s and to offer Novo products at parity with other telehealth channels; that reduces legal risk but may limit some prior channels/margins. Inc: Concession details
• Negative Sentiment: Ongoing legal and corporate risk — A shareholder/litigation investigation (Kahn Swick & Foti) into Hims’ officers and directors was announced, keeping potential governance and liability risk on the table despite the Novo settlement. Business Wire: KSF investigation
• Negative Sentiment: Profitability and sustainability concerns — Several outlets warn today’s rally may be unsustainable once the short squeeze pressure fades; fundamental recovery depends on successful commercialization and margin capture of Novo products. Invezz: Sustainability warning

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.